Auris Medical to Report Third Quarter 2018 Financial Results and Provide Business Update on Thursday, November 15, 2018
08 Novembro 2018 - 10:00AM
Zug, Switzerland, November 08, 2018 - Auris
Medical Holding AG (NASDAQ: EARS), a clinical-stage company
dedicated to developing therapeutics that address important unmet
medical needs in neurotology and mental health supportive care,
today announced that it will provide a business update and report
its financial results for the third quarter of 2018 on Thursday,
November 15, 2018. Following the announcement, Auris Medical's
management team will host a live conference call and webcast at
8:00 am Eastern Time (2:00 pm Central European Time).
To participate in this conference call, dial 1-877-407-0312
(toll free) or +1 201-389-0899, and enter passcode 13685071. A live
webcast of the conference call can be accessed in the Investor
Relations section of the Auris Medical website at
www.aurismedical.com. A replay will be available approximately two
hours following the live call.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical
company dedicated to developing therapeutics that address important
unmet medical needs in neurotology and mental health supportive
care. The company is focused on the development of intranasal
betahistine for the treatment of vertigo (AM-125) and for the
treatment of antipsychotic-induced weight gain and somnolence
(AM-201). These projects have gone through two Phase 1 trials and
will move into proof-of-concept studies in 2019. In addition, Auris
Medical has two Phase 3 programs under development: AM-111 for
acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner
ear tinnitus. The Company was founded in 2003 and is headquartered
in Zug, Switzerland. The shares of Auris Medical Holding AG trade
on the NASDAQ Capital Market under the symbol "EARS."
Investor contact: Joseph Green / Andrew GibsonEdison
Advisors for Auris Medical646-653-7030 / 7719jgreen@edisongroup.com
/ agibson@edisongroup.com
orinvestors@aurismedical.com
Auris Medical (NASDAQ:EARS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Auris Medical (NASDAQ:EARS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
Notícias em tempo-real sobre Auris Medical Holding AG da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de